Treatment with sorafenib and sunitinib in renal cell cancer: A Swedish register-based study

Medical Oncology

Volumn 30, Issue 1, 2013, Pages

  Ambring, Anneli ^a,b   Björholt, Ingela ^a   Lesén, Eva ^a   Stierner, Ulrika ^c   Odén, Anders ^d  

^a Nordic Health Economics   (Sweden)

^b Center of Registers in Region Vastra Gotaland   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d CHALMERS UNIVERSITY OF TECHNOLOGY   (Sweden)

Author keywords

Register; Renal cell cancer; Sequential; Sorafenib; Sunitinib

Indexed keywords

SORAFENIB; SUNITINIB;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CONTROLLED STUDY; DRUG CHOICE; DRUG DOSE SEQUENCE; FEMALE; HUMAN; KIDNEY CARCINOMA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RISK FACTOR; SWEDEN; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INDOLES; KAPLAN-MEIER ESTIMATE; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRROLES; SWEDEN; YOUNG ADULT;

EID: 84871145008     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0331-8     Document Type: Article

References (22)

1. Socialstyrelsen [National Board of Health and Welfare]. Cancer i siffror 2009 [Cancer in numbers 2009]. ISBN: 978-91-89446-36-6. Stockholm, Sweden: 2011.
2. Campbell SC, Flanigan RC, Clark JI. Nephrectomy in metastatic renal cell carcinoma. Curr Treat Options Oncol. 2003;4:363-72.
3. Escudier B, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356:125-34.
4. Escudier B, et al. Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol. 2009;27:3312-8.
5. Motzer RJ, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
6. Motzer RJ, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med. 2007;356:115-24.
7. Sablin MP, et al. Sequential sorafenib and sunitinib for renal cell carcinoma. J Urol. 2009;182:29-34.
8. Zimmermann K, et al. Sunitinib treatment for patients with advanced clear-cell renal-cell carcinoma after progression on sorafenib. Oncology. 2009;76:350-4.
9. Nationella arbetsgruppen för njurcancer [National working group for renal cancer]. Nationellt vårdprogram - Njurcancer [National care program - Renal cancer]. ISBN: 978-91-85947-19-5. Stockholm, Sweden; 2010.
10. Hutson TE, Bukowski RM, Cowey CL, Figlin R, Escudier B, Sternberg CN. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit Rev Oncol Hematol. 2011;77:48-62.
11. Buchler T, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Ann Oncol. 2012;23:395-401.
12. Dudek AZ, Zolnierek J, Dham A, Lindgren BR, Szczylik C. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. Cancer. 2009;115:61-7.
13. Filson CP, Redman BG, Dunn RL, Miller DC. Initial patterns of care with oral targeted therapies for patients with renal cell carcinoma. Urology. 2011;77:825-30.
14. Herrmann E, et al. Sequential therapies with sorafenib and sunitinib in advanced or metastatic renal cell carcinoma. World J Urol. 2011;29:361-6.
15. Porta C, et al. Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int. 2011;108:E250-7.
16. Calvani N, et al. Sequential use of sorafenib and sunitinib in advanced renal cell carcinoma: does the order of sequencing matter? Med Oncol. 2012;29:1908-13.
17. Buchler T, et al. Objective response and time to progression on sequential treatment with sunitinib and sorafenib in metastatic renal cell carcinoma. Med Oncol. 2012;29(5):3321-4.
18. Suissa S. Immortal time bias in pharmaco-epidemiology. Am J Epidemiol. 2008;167:492-9.
19. Läkemedelsindustriföreningens Service AB (LIF). Farmaceutiska Specialiteter i Sverige (FASS) [Swedish medicines information portal].
20. Oden A, Dawson A, Dere W, Johnell O, Jonsson B, Kanis JA. Lifetime risk of hip fractures is underestimated. Osteoporos Int. 1998;8:599-603.
21. Bhojani N, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol. 2008;53:917-30.
22. Karaman MW, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol. 2008;26:127-32.